Oxford coronavirus vaccine will "protect 95 per cent of patients" and is "as effective as the Pfizer and Moderna" alternatives, Pascal Soriot, chief executive of AstraZeneca, told British daily The Sunday Times. He added saying that the scientists had figured out a "winning formula to get efficacy up there with everybody else". However, AstraZeneca, a British-Swedish pharma giant, has yet to release data confirming these claims. Interim results of Phase III trials released last month showed a 70 per cent efficacy rate as the average of two dosing regimens. One of these regimens - a half dose followed by a full dose - showed 90 per cent efficacy, while Pfizer's data showed 95 per cent and Moderna's 94.5 per cent. Watch the video to know more.
Google Trends